Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model

Documenti analoghi

• Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
  di: Vandeveer, Amanda, et al.
  Pubblicazione: (2015)
• Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
  di: Boyerinas, Benjamin, et al.
  Pubblicazione: (2014)
• Systemic Immunotherapy of Non–Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor
  di: Vandeveer, Amanda J., et al.
  Pubblicazione: (2016)
• Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
  di: Fallon, Jonathan K., et al.
  Pubblicazione: (2017)
• Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells
  di: Boyerinas, Benjamin, et al.
  Pubblicazione: (2015)